The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
958
September 29, 1995
View Complete Issue         Table of Contents 2019 
Intracavernous Injection of Alprostadil for Erectile Dysfunction
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Intracavernous Injection of Alprostadil for Erectile Dysfunction
September 29, 1995 (Issue: 958)
An aqueous formulation of alprostadil (prostaglandin E 1 ; - Upjohn) has been approved by the US Food and Drug Administration (FDA) for injection into the corpus cavernosum to treat erectile dysfunction. The drug is also marketed as Prostin VR, an...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Intracavernous Injection of Alprostadil for Erectile Dysfunction
Article code: 958a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.